Mental Health
Grief and Growth: Geneva Walker Discusses Holding Pain and Purpose on Rock Solid Podcast
Geneva Walker, founder of Victorious Walk Counseling, shares her framework for processing grief while pursuing purpose in Episode 77 of the Rock Solid Podcast, offering timely insights amid rising anxiety and isolation.
Helus Pharma CMO to Speak at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma's Chief Medical Officer will present at a key industry conference, highlighting the company's progress in developing novel treatments for depression and anxiety.
SevensCutAbove Opens at Salon and Spa Galleria in Weatherford, Offering Sensory-Safe Haircuts
Licensed barber Seven Nelson launches SevensCutAbove in Weatherford, Texas, specializing in sensory-safe cuts and personalized services for clients with special needs or haircut trauma.
Dianetics Volunteers Extend Mental Health Outreach Beyond Awareness Month in Sacramento
Volunteers from the Hubbard Dianetics Foundation of Sacramento continued offering stress tests and educational materials after Mental Health Awareness Month, highlighting the ongoing need for practical mental wellness tools in the community.
Nashville Concierge Medicines Launches New Content on Adult ADHD Treatment
The clinic announces new online resources addressing adult ADHD, highlighting that symptoms can persist from childhood and differ between genders, emphasizing holistic, personalized care.
Dianetics Volunteers Conclude Mental Health Awareness Month with Community Outreach in Ventura
Volunteers from the Hubbard Dianetics Foundation of Ventura offered practical stress management tools during a weekend outreach, highlighting the ongoing need for mental health resources beyond May.
Watchdog Warns Psychiatry May Thwart Federal Antidepressant Deprescribing Plan
The Citizens Commission on Human Rights warns that psychiatry's history of downplaying drug risks could undermine HHS's May 2026 plan to address overprescribing and support safe antidepressant deprescribing.
Mental Health Practices Adapt to Rising Demand for LGBTQIA2S+ Affirming Therapy
Rising Sun Therapy & Wellness expands trauma-informed and identity-aware services to meet the growing need for inclusive mental health care for LGBTQIA2S+ individuals, couples, and families.
PhillComm Global Adds Personal Security Platform Bond and Mental Health AI Startup Klarify to Client Roster
PhillComm Global expands its portfolio with Bond, a preventative personal security platform, and Klarify, an AI operating system for mental health providers, addressing systemic challenges in personal safety and healthcare administration.
Colombia Nonprofit Integrates Mental Health Into Community Empowerment Model
Centro de Transformacion Integral launches a structured initiative combining mental health support, education, and social programs to address interconnected community challenges across Colombia.
Understanding Paragraph B Criteria Crucial for Mental Health Disability Claims, Pekas Smith Advises
Pekas Smith explains the SSA's Paragraph B criteria for mental health disability claims, emphasizing the importance of documented functional limitations for successful benefits eligibility.
Optimi Health Welcomes Australia's TGA Framework Update, Expanding Psychedelic Therapy Access
Optimi Health Corp. highlights Australia's updated TGA framework for psilocybin and MDMA, which broadens therapy teams and treatment settings, potentially accelerating adoption of psychedelic-assisted therapy.
Optimi Health Corp. Featured in Diamond Equity Research Initiation Report Highlighting Commercial Psychedelics Opportunity
Optimi Health Corp. (NASDAQ: OPTH) is highlighted in a Diamond Equity Research report for its role as a commercial-stage psychedelic manufacturer with GMP infrastructure, growing traction in Australia, and potential operating leverage as prescription demand scales.
Optimi Health Prices $15 Million Public Offering for Nasdaq Uplisting, Aims to Scale Psychedelic Drug Production
Optimi Health Corp. has priced a $15 million public offering as it uplists to the Nasdaq Capital Market, planning to use proceeds to expand production and distribution of its GMP-grade psychedelic drug products for mental health therapies.
Lucent Psych Expands Telepsychiatry Services to Seattle and Texas, Improving Mental Health Access
Lucent Psych expands online psychiatry to Seattle, WA, and Round Rock, Cedar Park, and Cypress, TX, aiming to increase access for conditions like ADHD, anxiety, depression, and PTSD.
MindBio Therapeutics Highlighted for AI-Powered Voice Analysis to Detect Impairment
MindBio Therapeutics Corp. is featured in a BioMedWire editorial for its AI-driven voice analysis technology that can detect drug and alcohol intoxication in real-time, offering a scalable alternative to traditional impairment testing methods.
Wisconsin’s First Dedicated Emergency Mental Health Facility Opens in La Crosse
Emplify Health by Gundersen opens EmPATH, the state’s first emergency mental health facility, providing dedicated crisis care within 23 hours.
Gillian Ragan Foundation to Host First Community Fundraiser at Pinnacle Brewing Company
The Gillian Ragan Foundation, supporting families who lost a child, will hold its inaugural fundraiser on May 17, 2026, featuring a hybrid silent auction to fund mental health therapy and grief counseling.
Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Alignment with Executive Order on Mental Health
Helus Pharma issued a correction to its partnership announcement with TARA Mind, removing references to Veterans Exploring Treatment Solutions while reaffirming the collaboration's support for Phase 3 recruitment in major depressive disorder and alignment with a recent executive order on mental health treatments.
Helus Pharma Partners with TARA Mind to Boost Veteran Recruitment in Phase 3 Depression Trial
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 trial of HLP003 for major depressive disorder, aligning with a recent executive order on mental health.
Helus Pharma Appoints Robert Langer and Stephen Brannan to Scientific Advisory Board, Bolstering Neuroscience Pipeline
Helus Pharma adds renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its drug development capabilities for mental health treatments including major depressive disorder and generalized anxiety disorder.
Loneliness Identified as Risk Factor for Degenerative Heart Valve Disease
New research reveals that loneliness, distinct from social isolation, is associated with a significantly higher risk of developing degenerative heart valve disease, suggesting it could be a modifiable risk factor with important implications for prevention and treatment strategies.
NRx Pharmaceuticals Receives Positive FDA Review for Ketamine ANDA, Targets 2026 Approval
NRx Pharmaceuticals has received a positive FDA review letter for its ketamine ANDA and reported a supportive meeting with FDA leadership, advancing its preservative-free ketamine product toward potential approval in summer 2026 for treating severe mental illness.
MindBio Therapeutics Expands AI Intoxication Detection with New Data Collection Platform
MindBio Therapeutics has launched Intox Collect™, broadening its AI-driven intoxication detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants, with implications for workplace safety across high-risk industries.
New Book Addresses Mental Health Crisis Through Faith-Based Approach
Dr. Walter Malone Jr.'s new book 'Tailored to Win' offers biblical solutions to rising anxiety and depression rates, providing practical guidance for finding purpose and spiritual strength.
Cybin Reports Strong Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
Cybin Inc. has reported strong institutional demand in its second-quarter 2025 results while advancing multiple late-stage clinical programs for mental health treatments, positioning the company for key 2026 data readouts that could significantly impact neuropsychiatry treatment options.
Cybin to Present Neuropsychiatry Pipeline at Jefferies Global Healthcare Conference
Cybin Inc. will present its late-stage neuropsychiatry pipeline including breakthrough-designated depression treatment at the Jefferies Global Healthcare Conference, highlighting the company's progress in developing novel mental health therapies.
Former NASA Engineer Releases Book on Anxiety Relief Through Energy Therapy
Mark L. Fox, former Space Shuttle Chief Engineer, has published a book promoting PEMF therapy as a drug-free solution for anxiety, chronic pain, and sleep disorders based on two decades of research.
CDC Data Debunks Holiday Suicide Myth as International Survivors Day Highlights Need for Accurate Information
New analysis reveals suicide rates are actually lowest in December, challenging persistent media narratives about holiday suicide spikes while raising concerns about antidepressant usage and suicide prevention effectiveness.
HOPE Therapeutics Launches Revolutionary One-Day Depression Treatment Protocol in Florida
NRx Pharmaceuticals' subsidiary HOPE Therapeutics has initiated Florida's first deployment of a rapid one-day TMS protocol for treatment-resistant depression, potentially transforming care for millions suffering from depression and PTSD.